The Board of ClouDr Group Limited announced the launch of ClouD GPT, an intelligent diagnostics technology powered by ClouDr Machine Learning Infrastructure and formed part of the ClouDr Brain. After extensive and specialized training in medical data, ClouD GPT is able to deal with complex and multi-modal situations. So far, the Company has applied ClouD GPT in software-as-a-service (SaaS) installations in hospitals and in online hospitals with a focus on clinical decision supporting system (CDSS).

As a hospital SaaS, ClouD GPT analyzes patients' conditions holistically, provides early warnings and suggestions for treatment plans of similar diseases and assists doctors in giving faster and more accurate diagnosis and treatment plans. In its application in online hospitals, ClouD GPT assists doctors and pharmacists in providing prescription quality control and improves the efficiency and accuracy of the doctors' diagnosis and treatment plans. The Board announced that its ClouD DTx Platform, powered by ClouDr Machine Learning Infrastructure and formed another part of the ClouDr Brain, has been applied to AI-assisted drug and device research and development, providing several key technical solutions for digital medical care for chronic diseases.

The digital therapy of ClouDTx-CVD has also been successfully developed for treating cardiovascular diseases. From the research results published in the Journal of Medical Internet Research (JMIR) on April 12, 2023, a multicenter clinical study found that after being in the digital therapy of ClouDTx-CVD for six months, the low-density lipoprotein C (LDL-C) levels of patients with cardiovascular diseases in the digital therapy treatment group decreased by 10%, compared with the control group (P<0.05), and the LDL-C normality rate was significantly higher than that of the control group (P<0.05). This is the first clinical study on the use of digital therapy to intervene blood lipids in cardiovascular disease treatment and proves that digital therapy is an effective complement to existing clinical treatment options for patients with cardiovascular diseases.

The research and development of the technologies discussed above was funded by internal resources of the Group.